Program
FGFR2/3 Inhibitor CGT4859
Its studies are mostly in Cholangiocarcinoma, led by Cogent Biosciences.
Furthest: phase 2, since Jan 9, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cogent Biosciences | 11 open or running | phase 2since Jan 9, 2025 | Jan 9, 2025 | Mar 2027phase 2 · NCT06777316 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2025First study: phase 2 study in CholangiocarcinomaFirst studyNCT06777316 · 110 enrolled · United States, Canada
Ahead
- Mar 2027Primary completion: phase 2 study in CholangiocarcinomaNCT06777316
TargetBeta
FGFR2 →read by rule
“An orally bioavailable reversible inhibitor of fibroblast growth factor receptor (FGFR) types 2 and 3 (FGFR2/3), ”NCIt, by rule
Other programs on FGFR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| pemigatinibrule | Incyte | phase 3 | 16 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| lirafugratinibrule | elevar-therapeutics | phase 2 | 2 |
| KNT-0916rule | kinoteck-therapeutics-co-ltd | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06777316Cholangiocarcinoma · United States, Canada | 2 | Active, not recruiting | Mar 2027 | 110 |
How it is read
Names in the registry
- “CGT4859”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.